Relevant Targets:
Primary: Arginase 1 Deficiency (ARG1-D) / Hyperargininemia
Secondary: Urea cycle disorders (UCDs) and other Amino Allies - This review may also be relevant to families following developments in rare metabolic therapies, reimbursement access, and Canadian drug review processes.
What this means for Canadians
Canada's Drug Agency (CDA-AMC) has released patient and clinician input submissions related to pegzilarginase, a therapy under review for arginase 1 deficiency (ARG1-D), also known as hyperargininemia. The document includes perspectives from patient organizations, clinicians, and community stakeholders describing the lived experience of ARG1-D and the need for additional treatment options in Canada.
The submissions highlight the significant burden associated with ARG1-D, including neurological complications, spasticity, developmental impacts, seizures, mobility challenges, and the ongoing demands of dietary and medical management. Contributors also described the emotional, social, and financial impact on families and caregivers.
Pegzilarginase is currently under active reimbursement review in Canada. The requested indication is for adults, adolescents, and children aged 2 years and older living with ARG1-D. CDA-AMC timelines currently include ongoing review milestones through 2026.
For Canadian families affected by ARG1-D and related urea cycle disorders, this review process represents an important step in evaluating whether pegzilarginase may eventually become publicly reimbursed and accessible within Canada.
English note: The CDA-AMC patient and clinician input document is currently available in English only.
Note en francais : Le document d'observations des patients et des cliniciens de l'ACMTS est actuellement disponible uniquement en anglais. Les communautes francophones peuvent toutefois consulter le resume prepare par CanPKU+/CanPCU+ et utiliser des outils de traduction en ligne si elles souhaitent lire le document complet.
Article
CDA-AMC Reimbursement Review: Patient and Clinician Group Input for pegzilarginase (ARG1-D)
This document compiles submissions from patient organizations and clinicians as part of Canada's Drug Agency's reimbursement review process for pegzilarginase.
Pegzilarginase is being reviewed for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents, and children aged 2 years and older.
The patient and clinician submissions describe the serious medical and daily living impacts associated with ARG1-D. Contributors highlighted neurological complications, developmental concerns, mobility challenges, speech and communication difficulties, seizures, and the burden of strict metabolic management. :contentReference[oaicite:3]{index=3}
The document also discusses the limitations of current treatment approaches, including dietary restriction, formula use, ammonia management, and supportive therapies. Patient and clinician groups emphasized the need for additional treatment options that may help improve metabolic control and quality of life. :contentReference[oaicite:4]{index=4}
CDA-AMC noted that the reimbursement review for pegzilarginase remains active, with additional review milestones and committee discussions scheduled throughout 2026. :contentReference[oaicite:5]{index=5}
Continue reading the full document at:
https://www.cda-amc.ca/sites/default/files/DRR/2026/SR0923_pegzilarginase_Patient_Clinician.pdf
Download the full document from here
